Acute Eosinophilic Pneumonia Associated With SARS-CoV-2 Infection

Descalzo, Vicente; Salvador, Fernando; Sansano, Irene; Persiva, Oscar; Antón, Andrés; Clofent, David; López, María Cristina Lorente; Almirante, Benito

doi:10.1016/j.arbres.2020.12.009

Cited by 11 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was a considerable rise in eosinophils, especially in BAL fluid in the two cases described above and in blood in the case reported (knowing that the eosinophil's count in the prior was about 330/mm 3 ). This can be explained by the virus itself [ 8 , 9 ] or the presence of allergic excipients [ 4 ], including polysorbate 80 in our case [ 10 ]. Unfortunately, we could not confirm eosinophilia in BAL fluid as the patient refused bronchial endoscopy.…”

Section: Discussionmentioning

confidence: 99%

Acute Eosinophilic Pneumonia Associated With the Anti-COVID-19 Vaccine AZD1222

Miqdadi

Herrag

2021

Cureus

View full text Add to dashboard Cite

SARS-CoV-2 is an emerging virus causing the contemporary global pandemic. No cure has yet been discovered. Therefore, vaccination remains the only hope. We report the case of a 66-year-old male patient with a history of allergies. Five hours after his vaccination with the anti-COVID-19 vaccine AZD1222 (ChAdOx1 nCoV-19, AstraZeneca), he developed acute respiratory distress. The biological assessment showed hyperleukocytosis, 20% of which are eosinophils. Diagnosis of severe postvaccination acute eosinophilic pneumonia was retained given the history of allergy, lack of improvement on antibiotics, elimination of all other probable causes of eosinophilia, and improvement on corticosteroids. Such reactions of eosinophilic pneumonia have only been described twice: once following vaccination with the influenza vaccine (Vaxigrip*) and the other after vaccination with the 23-valent pneumococcal polysaccharide vaccine (Pneumovax 23*). Hypereosinophilia must be taken into consideration, feared, and prevented. Although rare and severe, post-COVID-19 vaccination acute eosinophilic pneumonia remains well manageable with corticosteroids with a good outcome. Therefore, in some poorly monitored patients with allergy or asthma, the use of another less allergenic vaccine could be considered to avoid such reactions.

show abstract

Section: Discussionmentioning

confidence: 99%

Acute Eosinophilic Pneumonia Associated With the Anti-COVID-19 Vaccine AZD1222

Miqdadi

Herrag

2021

Cureus

View full text Add to dashboard Cite

show abstract

“…This case highlights an unusual association of AEP with a COVID-19 infection and the diagnostic challenges of unusual pneumonia during the pandemic [ 2 ]. To our knowledge, this association between AEP and COVID-19 has been reported only in two other case reports (Table 1 ) [ 3 , 4 ].…”

Section: Discussionmentioning

confidence: 72%

“…Hydroxychloroquine, azithromycin, or lopinavir/ritonavir could have caused AEP, but the authors argued against this since he improved while still on them. They argued that the steroids likely contributed to the low eosinophilic count in his BAL fluid [ 3 ].…”

Section: Discussionmentioning

confidence: 99%

Acute Eosinophilic Pneumonia Associated With COVID-19 Infection

Vogel¹,

El‐Kersh²

2022

Cureus

View full text Add to dashboard Cite

The knowledge about COVID-19 infection and sequelae is evolving. Acute eosinophilic pneumonia (AEP) is not a well-recognized complication of COVID-19 infection, with few cases reported in the literature. We report a case of a 60-year-old male with a history of an orthotopic heart transplant on chronic immunosuppression who had AEP three weeks after a COVID-19 infection. He presented with diarrhea and acute kidney injury without respiratory symptoms. After discharge, the patient experienced progressive fevers, dyspnea, and cough resulting in a second admission to the hospital with acute hypoxic respiratory failure requiring supplemental oxygen. Imaging demonstrated ground-glass opacities with areas of consolidation and bronchoalveolar lavage fluid demonstrated AEP. The patient was treated with steroids resulting in the resolution of his symptoms and radiographic findings. This case highlights the potential for AEP to complicate COVID-19 infections.

show abstract

“…To the authors’ knowledge, only two cases of acute eosinophilic pneumonia associated with SARS-CoV-2 have been described in the literature. 5 , 6 In our case, the patient presented a subacute onset of symptoms, initially presenting three weeks after the COVID-19 diagnosis with lung opacities and blood eosinophilia and then confirmed BAL eosinophilia. This patient was not taking any chronic medication and was not exposed to smoking, illicit drugs, or toxins and showed a dramatic response to corticosteroid treatment.…”

mentioning

confidence: 60%